Ongentys (opicapone) was recently approved by the FDA as an oral,add-on daily treatment for Parkinson’s patients experiencing off periods while on levodopa. Ongentys increases the amount of levodopa reaching the brain by blocking an enzyme called catechol-o-methyltransferase (COMT),that breaks down levodopa in the blood. Ongentys was found to be superior to placebo in reducing “off” periods — times when the beneficial effects of levodopa wear off before a new dose can be taken.
I already take COMTAN (entacapone), a generic COMT-blocking drug. Has Ongentys been compared directly to Comtan in any clinical trials? Is there any reason to believe Ongentys may be more effective at reducing off time, without increasing troublesome dyskinesias? I take Rytary plus Comtan six times per day, and I would welcome replacing those 6 Comtan tablets with a single Ongentys pill, if the symptomatic benefits are equal or better, and the price of Ongentys is not prohibitive compared to Comtan.
Parkinson’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.